TRANSFORM – the largest ever screening trial

Overview by Professor Hashim Ahmed
Chair in Urology and Consultant Urological Surgeon
Imperial College NHS Trust

 and Mr Nikhil Mayor
Academic Clinical Fellow
Urology Specialist Registrar
North London Deanery
Imperial College London

Hash introduces TRANSFORM

On 1 st May 2024, a landmark prostate cancer screening study was announced by Prostate Cancer UK: the TRANSFORM trial. The study is part of a major collaborative effort between some of the leading prostate cancer researchers in the UK and will be led by Professor Hashim Ahmed at Imperial College London.
The government-backed trial is supported by a £42 million grant from Prostate Cancer UK and co-funded by the National Institute for Health and Care Research, with support from a number of other prostate-focused organisations.

What is it?
TRANSFORM is one of the largest ever screening studies for prostate cancer and will involve over a quarter of a million men who will be followed up for over 10 years. The aim of the study is to find out the best way to screen men for
prostate cancer and in doing so, reduce the number of men dying from the disease. An initial pilot phase of the study will take place over three years and involve approximately 12,500 men. It will test whether standard prostate MRI
scans or new, shorter MRI scans can detect cancer in men from the general population who have no specific symptoms of prostate cancer. It will specifically look at the effect of MRI in men who have a normal or raised PSA blood test. The pilot will also review the impact of genetics, using simple blood tests called polygenic risk scores. This first phase of the study will help the researchers decide on the best screening tests to use in the main study.
It is expected that the study will run for at least 15 years to find out if screening can reduce deaths from prostate cancer. Importantly, it will also aim to find out which tests come with the least harm and are able to diagnose the most
dangerous cancers, without finding the low-risk cancers that can never impact patients. The team behind TRANSFORM expect it to be highly flexible so that if new screening tests become available, they can also be included in the trial.
Certain groups, such as men with weat african genetic heritage, which includes Afro Cabibeann men, are known to be at greater risk of dying from prostate cancer than the general population. As a result, the TRANSFORM trial
will specifically reach out to black men to ensure that they are well-represented in the study. By collecting samples, images, and data from over 250,000 men, TRANSFORM will also help build one of the largest prostate cancer biobanks in the world which will become available to researchers to help guide major new
discoveries.

Why do we need TRANSFORM?
There is currently no formal screening programme for prostate cancer in the UK. At present, the NHS website recommends men to see their GP if they have symptoms, at which point the GP may perform a prostate examination involving a  finger in the back passage (DRE), as well as a PSA test. This pathway has several flaws that may lead to the most dangerous cancers being missed. Firstly, prostate cancer has no symptoms in the vast majority of cases. Secondly, and most importantly, the PSA test is highly inaccurate. This is discussed in more detail on the “Screening for Prostate Cancer” page. In summary, the PSA test can miss life-threatening cancers (a false negative test) or can be raised when no cancer exists (a false positive test). False positive tests mean that men undergo invasive prostate biopsy for no reason. Worryingly, the PSA test can also be raised when low-risk cancers are present. These low-risk cancers are of such low likelihood to spread outside of the prostate that some urologists and pathologists debate whether they should even be called cancer! Unfortunately, some men with low-risk cancers will be treated when they don’t need to be: this is called overtreatment. Overtreatment is dangerous because treatments such as surgery or radiotherapy can come with significant side effects like erectile dysfunction and incontinence (leaking urine).
Large screening studies in the past have shown that PSA screening can reduce the number of deaths from prostate cancer by approximately 20%. But due to the serious risks of missing dangerous cancers and overtreating low-risk cancers, the UK National Screening Committee voted against screening with the PSA test alone in 2020.
TRANSFORM aims to change this. It is hoped that the new screening tools testing in TRANSFORM will increase the detection of life-threatening cancer whilst reducing unnecessary invasive biopsies and detection of low-risk cancers (and with that, reduce overtreatment).

When will it start?
Planning is already underway. The first phase of TRANSFORM will begin later this year with the first group of men invited to join in late 2024/early 2025.

Am I eligible for the trial?
If you are between the age of 50 and 75, or 45 for Black men, then you may be eligible. You won’t be able to volunteer for the trial, but letters of invitation will be sent out to eligible men via GP practices. TRANSFORM could save the lives of thousands of men every year. If you want to be part of this revolutionary study then please do respond to your letter of initiation when it arrives!